# Global Prevalence of ATTR-CM in Participants With HFpEF

> **NCT04424914** · NA · TERMINATED · sponsor: **Pfizer** · enrollment: 347 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DIAGNOSTIC_TEST:** Scintigraphy

## Key facts

- **NCT ID:** NCT04424914
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-30
- **Primary completion:** 2023-06-02
- **Final completion:** 2023-06-02
- **Target enrollment:** 347 (ACTUAL)
- **Why stopped:** Sponsor terminated study early to not prolong timelines and to enable sharing of data collected which has potential to better support understanding of the prevalence of ATTR-CM in patients with HFpEF. Decision was not based on any safety findings.
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04424914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04424914, "Global Prevalence of ATTR-CM in Participants With HFpEF". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04424914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*